Supreme Court limits FTC | Natural Products INSIDER naturalproductsinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from naturalproductsinsider.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
On Thursday, February 4, 2021, the Federal Trade Commission (FTC), with the concurrence of the Department of Justice’s Antitrust Division (DOJ), announced that it had suspended the process by which requests for early termination of Hart-Scott-Rodino Act (HSR Act) waiting periods are granted, potentially signaling a more aggressive approach to merger review.
Key Takeaways
For the foreseeable future, filing parties must in all cases wait for the full 30-day waiting period to expire before closing.
The rule applies to currently filed transactions and to any new filings.
The shift in practice by the FTC and the DOJ may preview a significant departure from the approach to merger enforcement under both Democratic and Republican administrations for decades.
Dec 16, 2020 8:52 AM PT
A demand for a massive amount of data from nine technology companies including Facebook and Twitter has been made by the Federal Trade Commission in what could be a prelude to regulation on the handling data by the industry.
The demand made Monday by the FTC seeks to obtain information on how many users the companies have, how active the users are, what the companies know about them, how they got that information, and what steps the companies take to continue to engage users.
The agency also wants to know how social media and video streaming companies process the data they collect and what kinds of inferences they are able to make about user attributes, interest and interactions.
Amazon pays $61 7 million to FTC to settle claims of withholding driver tips washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Health
your username
January 26, 2021
The Federal Trade Commission (FTC) has filed suit against Endo Pharmaceuticals, Inc., Endo International plc (together, Endo), Impax Laboratories, LLC, and Impaxâs parent company, Amneal Pharmaceuticals, Inc. (together, Impax), alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by jettisoning competition in the market for the drug oxymorphone extended-release (ER).
The Jan. 25 complaint, the public version of which was not available at the time of this writing, accuses the defendants of violating the Sherman and FTC Acts. According to the FTCâs press release, the heart of the illegal conduct centers around Endoâs agreement to stay out of the market in exchange for a cut of Impaxâs monopoly profits.